Novel Actions Of HDL Cholesterol: A Potential New Strategy For Treatment Of Diabetes
Funder
National Health and Medical Research Council
Funding Amount
$74,973.00
Summary
There are currently in excess of 170 million patients diagnosed with type 2 diabetes worldwide. Recent studies have identified novel actions of HDL cholesterol in relation to glucose and fat metabolism which provide a rationale for therapeutic approaches to raise levels of circulating HDL to manage the metabolic syndrome and type 2 diabetes. This research will investigate HDL signaling pathways and contribute significantly to our understanding of the metabolic actions of HDL in Humans.
Individualising Tyrosine Kinase Inhibitor Therapy In CML To Facilitate Successful Treatment Free Remission
Funder
National Health and Medical Research Council
Funding Amount
$376,449.00
Summary
This project will determine the optimal therapy for patients with chronic myeloid leukaemia (CML), matching the most appropriate drug to the individual patient, based on each patient's unique biology, thereby maximising the chance of cure. Furthermore, this project will develop novel highly sensitive tests for the presence of residual disease, even if undetectable by current techniques. This will enable crucial, timely treatment changes to be made with curative intent.
Combining Immune Profiling And Immunotherapy To Tackle Human Cytomegalovirus Infection In Transplant Patients
Funder
National Health and Medical Research Council
Funding Amount
$314,644.00
Summary
The proposed research aims to help transplant patients who are at high risk of cytomegalovirus (CMV) infection, using a treatment called adoptive immunotherapy. I seek to improve the function of patients’ own specialised immune cells (known as T cells) in laboratory and transfer the T cells back into patients, allowing them to better fight the CMV infection. This treatment will improve survival, minimise transplant rejection and reduce the cost associated with anti-viral drugs.
The MetaFIND (Metagenomics For INfectious Diseases) Project: Developing Clinical Metagenomics To Improve The Healthcare Of Patients With Infections
Funder
National Health and Medical Research Council
Funding Amount
$303,014.00
Summary
The MetaFIND (Metagenomics For INfectious Diseases) project is a combined laboratory and clinical study that aims to develop and investigate the use of cutting-edge genome sequencing technology to improve the healthcare of patients with severe infections. It involves developing and optimising a method to determine the cause of an infection by analysing all the DNA present in a clinical sample – a promising “one-stop-shop” test to help improve diagnosis and subsequent treatment of infections.
Enhancing The Cascade Of HIV Care To Maximise The Prevention Benefits Of Antiretroviral Therapy For Populations Living With HIV
Funder
National Health and Medical Research Council
Funding Amount
$344,644.00
Summary
Antiretroviral drugs are effective at preventing death and illness for populations with HIV and preventing HIV transmission. I will undertake a series of studies to measure the impact of current antiretroviral treatment to prevent both illness and new infections in Australia. I will also undertake a series of studies to increase HIV testing, diagnose HIV earlier, and improve people’s linkage and retention HIV in care and evaluate the impact of these interventions on HIV transmission.
A Phenomic And Genomic Approach To Identifying Pharmaceutical Targets For The Amelioration Of Hematopoietic Deficit
Funder
National Health and Medical Research Council
Funding Amount
$87,000.00
Summary
Mice and humans are genetically and physiologically similar, and are afflicted by many of the same diseases. By introducing random DNA mutations into the germline, mice with diseaseassociated characteristics can be generated, allowing the subsequent identification of genes involved in particular human disease processes. This project will utilise cutting-edge genetic technologies to discover genes that regulate production of the body�s principal blood clotting agents: platelets. This is of partic ....Mice and humans are genetically and physiologically similar, and are afflicted by many of the same diseases. By introducing random DNA mutations into the germline, mice with diseaseassociated characteristics can be generated, allowing the subsequent identification of genes involved in particular human disease processes. This project will utilise cutting-edge genetic technologies to discover genes that regulate production of the body�s principal blood clotting agents: platelets. This is of particular clinical and commercial importance since a reduction in platelet numbers is the life-threatening result of congenital and autoimmune diseases, viral infections (e.g. HIV) and cancer chemotherapy.Read moreRead less
The Role Of Expectation On Outcome In Patients With Musculoskeletal Disorders
Funder
National Health and Medical Research Council
Funding Amount
$388,334.00
Summary
What a patient expects from their health condition has an important influence on how well they do. These expectations are also thought to underpin placebo effects and several studies show that clinicians often make use of this in their daily practice. This research aims to explain how peoples' expectations influence the way they respond to different treatments. This information will help health professionals improve the the way they treat people with a range of different health problems.
Translating Cardiovascular Disease Prevention Guidelines Into General Practice: A Behavioural Intervention Within A Systems Approach To Improve Evidence-based Practice
Funder
National Health and Medical Research Council
Funding Amount
$318,768.00
Summary
This project will develop, evaluate and implement a combined GP and patient intervention to improve cardiovascular disease (CVD) prevention, by increasing: 1) use of CVD risk calculators; 2) guidelines-based prescribing of medication to high risk and not low risk patients; and 3) patient understanding of CVD risk/management options and involvement in decision making. This will improve care for millions of patients, reduce the cost of CVD, and develop new methods to improve other areas of health.